Hospira recalls drugs because of stainless particulate; China's WuXi sees manufacturing surge;

> Manufacturing continues to power earnings growth at WuXi PharmaTech. Story

> Hospira ($HSP) has voluntarily recalled one lot of labetalol hydrochloride injection, USP, 100 mg/20 mL (5 mg/mL) 20 mL to the user level because of stainless steel particulate found in a vial. Report

> Total Facility Solutions (TFS) has built a 20,000-square-foot certified hygienic fabrication facility in Burlington, NC. Report

> New Jersey-based PuraCap Pharmaceutical said that Max Baucus, U.S. Ambassador to China, last week visited the PuraCap Softgel Capsule Manufacturing Plant in Wuhan, China. Release

And Finally... Merck ($MRK) Animal Health said the FDA has approved its Bravecto, a chewable tablet for dogs that will kill fleas and some tick species for up to 12 weeks with a single dose. Release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.